The induction of apoptosis by p53 in response to cellular stress is its most conserved function and crucial for p53 tumor suppression. We recently reported that p53 directly induces oligomerization of the BH1,2,3 effector protein Bak, leading to outer mitochondrial membrane permeabilization (OMMP) with release of apoptotic activator proteins. One important mechanism by which p53 achieves OMMP is by forming an inhibitory complex with the antiapoptotic BclXL protein. In contrast, the p53 complex with the Bcl2 homolog has not been interrogated. Here we undertake a detailed characterization of the p53-Bcl2 interaction using structural, biophysical and mutational analyses. We identify the p53 DNA binding domain as the binding interface for Bcl2 using solution NMR. The affinity of the p53-Bcl2 complex was determined by surface plasmon resonance analysis (BIAcore) to have a dominant component KD=535±24 nM. Moreover, in contrast to wt p53, endogenous missense mutants of p53 are unable to form complexes with endogenous Bcl2 in human cancer cells. Functionally, these mutants are all completely or strongly compromised in mediating OMMP, as measured by cytochrome c release from isolated mitochondria. These data implicate p53-Bcl2 complexes in contributing to the direct mitochondrial p53 pathway of apoptosis and further support the notion that the DNA binding domain of p53 is a dual-function domain, mediating both its transactivation function and its direct mitochondrial apoptotic function.
The induction of apoptosis by p53 in response to cellular stress is its most conserved function and crucial for p53 tumor suppression. We recently reported that p53 directly induces oligomerization of the BH1,2,3 effector protein Bak, leading to outer mitochondrial membrane permeabilization (OMMP) with release of apoptotic activator proteins. One important mechanism by which p53 achieves OMMP is by forming an inhibitory complex with the antiapoptotic BclXL protein. In contrast, the p53 complex with the Bcl2 homolog has not been interrogated. Here we undertake a detailed characterization of the p53-Bcl2 interaction using structural, biophysical and mutational analyses. We identify the p53 DNA binding domain as the binding interface for Bcl2 using solution NMR. The affinity of the p53-Bcl2 complex was determined by surface plasmon resonance analysis (BIAcore) to have a dominant component KD=535±24 nM. Moreover, in contrast to wt p53, endogenous missense mutants of p53 are unable to form complexes with endogenous Bcl2 in human cancer cells. Functionally, these mutants are all completely or strongly compromised in mediating OMMP, as measured by cytochrome c release from isolated mitochondria. These data implicate p53-Bcl2 complexes in contributing to the direct mitochondrial p53 pathway of apoptosis and further support the notion that the DNA binding domain of p53 is a dual-function domain, mediating both its transactivation function and its direct mitochondrial apoptotic function.
A major function of the p53 tumor suppressor is the induction of an apoptotic program in response to a broad variety of cell stresses. Thus, understanding the mechanisms by which p53 executes cell death pathways are of considerable importance in cancer biology. The basis for p53's powerful apoptotic and tumor suppressor activity lies in its pleiotropism, which includes transcription-dependent and transcriptionindependent functions (1,2). p53-mediated apoptosis primarily signals through the mitochondrial pathway (1) . Some notable p53 target genes such as the BH3-only proteins PUMA, Noxa, Bax and p53AIP1 reside and/or act at the mitochondria (3) (4) (5) (6) (7) .
We previously showed that in response to a death stimulus such as DNA damage or hypoxia, a fraction of stabilized p53 rapidly translocates to mitochondria in primary, immortal and transformed cells (8) (9) (10) (11) .
The functional consequences of this phenomenon were revealed by targeting exogenous p53 to mitochondria in p53-null cells. Mitochondrially targeted p53 was sufficient to launch apoptosis and suppress colony formation directly from the mitochondrial platform in a transcription-independent fashion (9,10). Translocated endogenous mitochondrial p53 interacts with anti-apoptotic BclXL and Bcl2 proteins and blocks their functions. Purified p53 protein induces oligomerization of Bak, permeabilization of the outer mitochondrial membrane and strongly promotes cytochrome c release from healthy unstressed mitochondria (10) .
Using computational and mutational analyses, we previously reported that the p53 DNA binding domain (p53DBD) mediates the p53-BclXL interaction. Conversely, all tested tumor-derived and transactivation-deficient missense mutants of p53 concomitantly lose or severely compromise their ability to interact with BclXL and to promote OMMP. Thus, tumorderived p53 mutations may represent 'double hits', eliminating the transcriptional as well as the direct mitochondrial functions of p53 (10) . In vivo, mice treated with 5 Gy γ-irradiation or a single clinical dose of etoposide showed a rapid first wave of mitochondrial translocation of p53 in radiosensitive but not in radioresistant organs that correlated with early effector caspase activation and apoptosis of a subpopulation of cells. This first wave preceded the earliest detectable transcriptional response, e.g. PUMA in thymus, which then led to further caspase activation and cell death. Thus, mitochondrial p53 triggers a rapid apoptotic response that "jump-starts" and amplifies the slower transcription-based response (8, 12) .
Bcl2 and BclXL are the closest homologues in the Bcl2 family with 45% sequence identity and 56% sequence similarity. The two proteins have similar antiapoptotic functions at mitochondria and their expression levels are interrelated, i.e. the overexpression of one represses the other (13) . However, biological differences between the two exist. Overexpression of Bcl2 is associated with cell cycle arrest in G1 and cellular senescence (14, 15) , while BclXL overexpression suppresses TRAIL-induced apoptosis (16) . Bcl2 associated cycle arrest is mediated by the inhibition of Cdk2 and p27 Kip1 (17) . Moreover, a prognostic difference exists in certain cancers. In breast and small cell lung cancer patients, higher Bcl2 expression is paradoxically associated with better prognosis and accordingly, tumor grade is inversely correlated with Bcl2 levels (18, 19) . In contrast, BclXL expression correlates with higher tumor grade and increased number of nodal metastases in breast cancer (20) . Moreover, gene targeting studies in mice also reveal a significant functional differences between BclXL and Bcl2, emphasizing the notion that interaction results of BclXL cannot be blindly extrapolated to Bcl2 but need independent study. First, in myeloid progenitors cytokines selectively regulate BclXL -but not Bcl2 -and apoptosis by a Jak2 kinase-dependent pathway (21) . Second, loss of BclXL in mice results in high levels of apoptosis in embryonic hematopoietic cells (22) , whereas Bcl2-deficient mice display profound apoptosis of mature lymphocytes, which disappear by 4 to 6 weeks of age (23, 24) . Therefore, it is of great interest to understand to what extent Bcl2 and BclXL share overlapping functions and interact with the same set of protein partners.
Mutational, structural and biophysical investigations of the p53 complex with BclXL and Bcl2 help us understand what drives complex formation and how tumor-derived p53 mutations affect these interactions. Recently an NMR study confirmed our previous mutational and functional studies and showed that the DNA contact region of p53, where most of the tumor-derived mutations are concentrated, forms the interface with BclXL (10, (25) (26) (27) . Chipuk et al (28) determined the K D = 164 ± 54 nM for p53 dissociation from BclXL using surface plasmon resonance (BIAcore). Here we report that p53 utilizes the same DNA contact region to interact with Bcl2. Complex formation neutralizes the anti-apoptotic function of Bcl2 and induces mitochondrial permeabilization with cytochrome c release.
Materials and Methods
Mitochondrial purification and protein complex characterization. The human tumor cell lines ML-1 (wt p53), MDA 231 (p53 R280K), MDA 468 (p53 R273H), T47D (p53 L194F) and SKBr3 (p53 R175H) were grown in RPMI (ML-1) or DMEM plus 10% FBS. Mitochondria were prepared by discontinuous sucrose density gradients (9, 10, 29) . The following antibodies were used for immunoblotting and immunoprecipitation: monoclonal DO-1 (Santa Cruz Biotechn.) or polyclonal CM-1 (Vector) for p53, mt hsp70 (Affinity Bioreagents); PCNA (Santa Cruz), Cytochrome C (Pharmingen) and Cytochrome Oxidase IV (Mol. Probes), VDAC (Calbiochem), Bcl2 (Transduction Labs, monoclonal clone 7), and Bax (Neomarker). For endogenous complexes, mitochondria were solubilized in CHAPS buffer A (50 mM Tris pH 7.6, 150 mM NaCl, 1% CHAPS, protease inhibitor cocktail (Roche)). Lysates (1 mg) from Camptothecin-treated cells were diluted to 0.5% CHAPS buffer and immunoprecipitated with 1 µg antibody. Beads were washed 3 times with SNNTE (50 mM Tris pH 7.4, 5 mM EDTA, 500 mM NaCl, 5% sucrose, 1% NP40 ) then twice with RIPA (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0,1% SDS, 1% NaDeoxycholate, pH 7.4) and subjected to an initial Western blot for quantitation. Loading of the definitive blot was normalized for equal amounts of immunoprecipitated p53, and then blotted for Bcl2.
For co-purification using glycerol gradients, purified mitochondria from ML-1 cells stressed with 5 µM Camptothecin for 3.5 h were lysed in CHAPS buffer B (6 mM CHAPS, a nondenaturing concentration which preserves complexes; 150 mM KCl, 20 mM HEPES pH 8.0, 1 mM EDTA, 2 mM DTT, 5% Glycerol), loaded onto a 40%-15% glycerol gradient diluted in lysis buffer, centrifuged at 45,000 rpm for 14 h. Equal volume fractions were collected from the bottom of the tube and immunoblotted as indicated.
For immunoaffinity columns, 200 µg of mitochondrial lysates made with CHAPS buffer A were incubated with 20 µL of a 1:1 mixture of agarose beads covalently coupled to monoclonal p53 antibodies DO-1 and PAb1801 for 2 h, followed by extensive washing and elution with a 100 mM glycine buffer pH 3.6.
Cloning, protein expression and purification.
Residues 94-312 of the human p53DBD was subcloned into a modified pQE40 vector under the control of a T5 promoter (Qiagen) and expressed in E. coli BL21(DE3) co-transfected with the repressor plasmid pUBS520 (30, 31) . Unlabeled and uniformly 15 N-labeled p53DBD proteins were prepared as previously described (30, 32) .
Bcl2∆TM (residues 1-218, isoform 2 with Thr96 and Arg110 and without the transmembrane domain) was subcloned into pET30b (Novagen) and the large flexible loop of Bcl2 was replaced with the shorter loop of BclXL at the equivalent position as previously described (33) . In contrast to native Bcl2∆TM which was insoluble, this chimeric construct of Bcl2 was soluble and also retained its native biological functions (33) . Briefly, the protein was purified via Ni-NTA resin (Qiagen), the His-Tag was cleaved off by thrombin digestion and free Bcl2∆TM was further purified by ion-exchange and size exclusion columns as described (33) .
Two recombinant BclXL proteins were overexpressed from pET (Novagen) expression vectors with an N-terminal His-tag. In these constructs the putative C-terminal membraneanchoring region (residues 214-237) was removed (BclXL∆TM). In a second version, the large flexible loop was also shortened by removing residues 49-88 (BclXL∆LP∆TM). This loop was previously shown to be dispensable for the antiapoptotic activity of the protein (34) . Proteins were purified as for Bcl2.
As a measure of quality control, recombinant BclXL∆LP∆TM, BclXL∆TM and Bcl2∆TM proteins bound to the 16-mer Bak peptide with similar affinities as the commercial BclXL and Bcl2 proteins (Santa Cruz Biotech) in the fluorescence polarization (FP) assay (33) .
For cytochrome c release assays, full length p53s with missense mutations in the DNAbinding domain were generated by site directed mutagenesis and sequence confirmed. Constructs were cloned into pET15b, and expressed in E. coli BL21(DE3). Wild type and mutant proteins were purified by Ni-NTA chromatography. Protein purity and integrity was assessed by Coomassie stained SDS PAGE gels and DO1 immunoblotting.
NMR spectroscopy NMR spectra for 15 N-labeled p53DBD complexed with unlabeled Bcl2 were acquired at 293 K in sample buffer (25mM Na Phosphate (pH 7.2), 150 mM KCl, and 5 mM DTT) on Avance Bruker spectrometers (500 and 750 MHz 1H frequency) equipped with a tripleresonance and xyz-gradient probe. All experiments were processed and analyzed by nmrPipe and nmrDraw software (35 Cytochrome c release assay Freshly harvested livers of 10 weeks old C57BL/6 mice were used to prepare isolated mitochondria by discontinuous sucrose gradient. Cytochrome c release assays with mutant and wild type p53 proteins were performed as described (10 
Surface plasmon resonance (SPR) measurements.
Biacore 1000 (Biacore AB) for surface plasmon resonance (SPR) measurements and Scrubber (v 1.1g, Center for Biomolecular Interaction Analysis, University of Utah) were used for surface plasmon resonance analysis; BIAeval (v 4.1, Biacore AB) software was used for kinetic analysis.
RESULTS AND DISCUSSION
We previously co-immunoprecipitated specific endogenous complexes between wtp53 and Bcl2 from human cells (10) . To verify that p53 and Bcl2 interact at mitochondria, we performed glycerol gradient centrifugation on solubilized proteins from purified mitochondria of ML-1 cells that had been briefly subjected to DNA damage (5 µM camptothecin for 3.5 h), and looked for co-migration of endogenous p53 and Bcl2. When proteins were extracted from purified mitochondria by 6 mM CHAPS (a non-denaturing zwitterionic detergent that preserves protein complexes) and resolved on a 40-15% glycerol gradient, p53 and Bcl2 proteins co-migrated in fractions 9 and 10 ( Fig. 1A) , supporting complex formation. To further confirm complex formation, the proteins extracted from CHAPS-solubilized mitochondria were subjected to p53 immunoaffinity chromatography. A mixture of p53 specific monoclonal antibodies covalently coupled to agarose beads was used to capture endogenous protein complexes. After extensive washing, p53 and Bcl2 co-eluted from the column (Fig. 1B) . Together, these data confirmed our previous detection of an endogenous p53-Bcl2 complex, isolated from NP40-solubilized purified mitochondria (10) .
To gain structural insight into the p53-Bcl2 interaction and to localize the protein-protein interface, we used nuclear magnetic resonance (NMR) spectroscopy (30) . Our NMR data identify the DNA contact surface of the p53 DNA binding domain (DBD) as the binding site for Bcl2 (Fig.  2A, B) . Upon titration of unlabeled Bcl2∆TM to uniformly 15 N-labelled p53DBD, Bcl2∆TM induced chemical shift perturbations in the 15 N HSQC spectra of p53DBD. This indicates that Bcl2∆TM directly binds to p53 and that the interaction is specific. We did not observe large global chemical shift perturbations, suggesting that binding of Bcl2∆TM does not induce major conformational rearrangements of p53DBD. Some signals corresponding to the interacting p53 residues disappeared instead of shifting. (Fig. 2A) , which implies that the p53/Bcl2 complex formation is in the intermediate exchange regime on the NMR chemical shift time scale (in the millisecond range). The affected residues were Gln-136, Ala-138, Ala-161, Tyr-163, Cys-176, His-179, Ile-195, Tyr-236, Met-237, Asn-239, Gly-244 and Thr253. Thus, they localize on the DNA contact interface of the p53DBD (Fig. 2B) .
These data align with the recent NMR study of the p53-BclXL complex by Petros et al (25) , which determined chemical shift perturbations in p53DBD upon addition of BclXL. We were able to reproduce their results (data not shown). Neither p53 nor BclXL undergo a major conformational change upon binding. The chemical shift changes caused by the BclXL interaction were at the residues Arg-280, Cys-277, Ser-241, Cys-238, Cys-182 and Val-173. Thus, as had been predicted by mutational and modeling studies (10) , residues within the DNA binding interface of p53 form the contact site with the acidic 'underside' of BclXL, comprised of the Cterminal end of the BH4 domain and the two loops between the α3 and α4 helix and the α5 and α6 helix (25) . This region is distinct from the hydrophobic binding pocket for BH3-domain containing proteins.
Direct physical interaction between Bcl2 and wtp53 was also verified by surface plasmon resonance. Quantitative analysis of experimental BIAcore data indicated that there were fast and slow components in the sensorgram. We therefore used a model of two parallel heterogeneous ligand reactions in the kinetic analysis to separate the two components in the SPR data. Bcl2∆TM interacted with wtp53DBD with a K D1 = 535±24 nM for the dominant fast component and a K D2 = 16.9±0.40 µM for the minor slow component (Fig. 3) . (Since K D2 is about 30-fold larger than KD1, we can safely neglect this still measurable but small component in the system). This level of affinity between Bcl2∆TM and p53, i.e. a K D1 in the hundred nanomolar range, is consistent with an immunoprecipitable endogenous p53-Bcl2 complex and with our NMR result, where the peaks in the p53 spectra affected by Bcl2 underwent exchange broadening and some peak intensities were weakened beyond the limits of detection. We could confirm a slightly stronger affinity between BclXL∆TM and wtp53DBD (data not shown), which was recently reported to have a K D = 164±54 nM for full-length wtp53 and 6xHis-BclXL∆TM (28) . Interestingly, even though the large flexible loop in BclXL is very close to the p53 binding site, we found that the presence or absence of the loop did not alter the BclXL affinity to p53 significantly (data not shown).
We next tested whether a BH3 peptide that binds to Bcl2 with a higher affinity than p53 affects the interaction between p53 and Bcl2. We used the 21-mer BH3 domain peptide of Bid. This peptide bound to Bcl2∆TM with a K D of 15.7 nM in our FP assay. First, the p53-Bcl2 complex was preformed as above by adding unlabelled Bcl2∆TM to 15 N-labeled p53DBD. After titrating in the Bid peptide to the p53-Bcl2 complex, the missing or shifted peaks of p53 were gradually restored towards their original intensities and positions (e.g. A138 and Y163; Fig. 2C) , indicating that the Bid peptide can induce the dissociation of Bcl2 from p53 due to its stronger interaction with Bcl2.
We next determined the functional consequences of the p53-Bcl2 interaction at the mitochondria and the impact of cancer-associated p53 mutations. Of note, in contrast to stressinduced wt p53, tumor-derived p53 mutants, despite drastically elevated levels of mutant protein for most mutants, were incapable of undergoing the p53-Bcl2 complex formation, irrespective of the absence or presence of DNA damage (Fig. 4 top and data not shown) . To this end, p53-harboring ML-1 cells or mutant p53-harboring breast cancer cells (MDA 231, MDA 468, T47D and SKBr3), representing various naturally occurring missense mutations including the hotspot structural and contact p53 mutants, were stressed with 5 µM Camp for 3.5 h. Cell lysates were then immunoprecipitated for p53. After normalization, equal amounts of immunoprecipitated p53 from these various sources were blotted for Bcl2. As shown in Fig. 4 top, mutant p53 R280K, R273H, R175H and L194F were all completely defective in this interaction, despite comparable levels of endogenous Bcl2 protein expressed in all cell lines, including ML-1 (Fig. 4 bottom) .
To gain functional insight into the p53-Bcl2 complex, we undertook permeabilization studies on freshly isolated mouse liver mitochondria using purified recombinant p53 proteins at increasing concentrations. As expected, wt p53 induced a dose-dependent release of cytochrome c from mitochondria (Fig. 5) . In sharp contrast, p53 R175H was completely inactive for the cytochrome c release and p53 R273H was severely suppressed in this activity. Moreover, p53 L194F and R280K, as well as four additional mutants not previously tested (G245S, R248W, R249S and R282W) were all completely or strongly compromised in mediating OMMP. These results confirm and extent our previous observation on p53 R175H and p53 R273H (10) . Thus, in summary, a complete correlation existed between the inability of mutant p53s to engage in Bcl2 complexes (see Fig. 4 ) and the concomitant inability to induce OMMP and cytochrome c release, supporting the physiologic importance of the p53-Bcl2 complex formation.
Concerning the p53 R175H mutant, it is worth noting that in our earliest study, we had found that the ectopically expressed L-version of the p53 mutant R175H, consisting of a fusion of p53R175H with the mitochondrial import leader signal sequence from ornithine transcarbamylase, was able to induce apoptosis in SaOs2 p53 null cells (9) . We since showed that this was an aberrant result due to supra-physiological expression levels. This fusion protein, which was only one of many mutants tested since, expresses at exceedingly high levels in cells, much higher than endogenous mutants do. As a result, L-p53 R175H forms aberrant non-specific complexes with BclXL, explaining its aberrant apoptosis in SaOs2 cells (9) . Importantly, however, the apoptosis observed with this L-version of the 175 mutant disagreed with all our subsequent results, where the same R175H mutant was tested in a physiological setting in several different assays: In contrast to wt p53, i) the naturally occurring (nontargeted) Rl75H mutant in the breast cancer cell line SKBr3 lacked apoptotic activity and was unable to form a BclXL (10) and Bcl2 complex (Fig. 4) ; ii) The nuclear R175H mutant, transfected into H1299 p53 null cells, also lacked apoptotic activity and was unable to form a BclXL complex (10); and iii) purified baculoviral R175H mutant p53 protein failed to release cytochrome c (10) .
Thus, as summarized in Table 1 , all eight tumor-derived p53 mutant proteins tested to date have lost the ability to promote cytochrome c release from mitochondria. Four of these mutants were already shown to be doubly defective in BclXL and Bcl2 complex formation (Ref. (10) and Fig. 4 ). An additional mutant (p53 R248W) was unable to form a BclXL complex. Thus, structural information from NMR spectroscopy is in complete agreement with this data, since the mutated residues all lie within or are located proximal to the binding interface of the complex. This direct link is very compelling, since it strongly argues that p53 mutations selected during tumorigenesis lose both the nuclear and mitochondrial apoptotic function of p53.
CONCLUSION
This structure/function analysis shows that p53 engages in a complex that neutralizes the death protective function of Bcl2. It identifies the p53 DBD as the binding interface for Bcl2, using solution NMR. In contrast to wild-type p53, tumor-derived missense mutants of p53 are unable to form complexes with endogenous Bcl2 in human cancer cells. Functionally, all p53 mutants are either completely or strongly compromised in mediating OMMP. These data implicate that both p53-Bcl2 and p53-BclXL complexes are contributing to the direct mitochondrial p53 pathway of apoptosis. Moreover, it further supports the notion that the DNA binding domain of p53 is a dual-function domain, mediating both its transactivation function and its direct mitochondrial apoptotic function. Fig. 1 Co-purification and co-elution from purified mitochondria of short term damaged cells indicate a complex between endogenous wt p53 and Bcl2. A. ML-1 cells were stressed with 5 µM Camp for 3.5 h, and mitochondria were isolated by sucrose gradient centrifugation. Purified solubilized mitochondrial proteins ("S") were resolved on a glycerol gradient. Fractions were immunoblotted as indicated. Co-migration of endogenous wt p53 and Bcl2 is seen in fractions 9 and 10. Proteins of 20 kD (fraction 12) to 600 kD (fraction 1) were resolved on this gradient. Non-complexed recombinant p53 and Bcl2 were found primarily in fractions 11 and 12, respectively (data not shown). "P" mitochondrial pellet. B. Co-elution of endogenous wt p53 and Bcl2 from a p53-affinity column (mixture of DO1 and PAb 1801 monoclonal antibodies) using lysates of purified solubilized mitochondria from ML-1 cells stressed with 5 µM Camp for 3.5 h. Fifty µl aliquots of elutions 1-3 were immunoblotted with polyclonal antibodies against p53 (CM-1) and Bcl2. 15 N HSQC signals of p53DBD upon titration with a 1.1-fold excess of Bcl2. Only p53 DBD residues are visible since Bcl2 is not labeled. Overlaid 15N HSQC spectra recorded on 15 N-labelled p53DBD in the absence (black) or presence (red) of unlabelled Bcl2. B. p53DBD residues perturbed upon titration of Bcl2 are mapped onto the crystal structure of p53DBD. They localize to the DNA contact surface of p53. C. Sections of overlaid 15 N HSQC spectra recorded on 15N-labelled p53DBD in the absence (black) or presence (red) of unlabelled Bcl2. Top: p53 with Bcl2 only; Bottom: p53 with Bcl2 and BH3 Bid peptide that binds to Bcl2. After addition of Bid peptide, the overall intensity of the spectrum is restored and some missing/shifted residues (e.g. A138 and Y163) are returned to their original positions. 
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